US Tech 100

19,500.00

-0.40%

Get Started

CVM Cel Sci Corporation New

1.08

0.035 (3.35%)

Last Updated: 11:34:33

Delayed by 15 minutes

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

null

Cel Sci (AMEX:CVM)
Historical Stock Chart
From Aug 2024 to Sep 2024

Cel Sci (AMEX:CVM)
Historical Stock Chart
From Sep 2023 to Sep 2024

Cel Sci Corporation New News

CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
Monday 16 September 2024 (2 weeks ago) • Business Wire

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
Tuesday 10 September 2024 (2 weeks ago) • Business Wire

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
Wednesday 4 September 2024 (3 weeks ago) • Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans
Friday 30 August 2024 (4 weeks ago) • Edgar (US Regulatory)

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
Thursday 15 August 2024 (1 month ago) • Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 14 August 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 29 July 2024 (2 months ago) • Edgar (US Regulatory)

CEL-SCI Announces Closing of $10.8 Million Offering
Monday 29 July 2024 (2 months ago) • Business Wire

Form 424B5 - Prospectus [Rule 424(b)(5)]
Monday 29 July 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 26 July 2024 (2 months ago) • Edgar (US Regulatory)

CEL-SCI Announces Pricing of $10.8 Million Offering
Friday 26 July 2024 (2 months ago) • Business Wire

CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
Friday 26 July 2024 (2 months ago) • Business Wire

More Cel Sci Corporation New News Articles

COIN

KEYSUST

Keys

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CVM Cel Sci Corporation New

Cel Sci Corporation New News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CVM Cel Sci Corporation New

Cel Sci Corporation New News

Your Recent History

Company

Business

Popular

Get The App